Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study

Background Ixazomib is the first oral, small molecule proteasome inhibitor to reach phase 3 trials. The current analysis characterized the exposure-safety and exposure-efficacy relationships of ixazomib in patients with relapsed/refractory multiple myeloma (MM) with a purpose of recommending an appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Labotka, Richard, Liu, Guohui, Hui, Ai-Min, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859859/
https://www.ncbi.nlm.nih.gov/pubmed/27039387
http://dx.doi.org/10.1007/s10637-016-0346-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859859/
https://www.ncbi.nlm.nih.gov/pubmed/27039387
http://dx.doi.org/10.1007/s10637-016-0346-7

Ejemplares similares